Photopheresis for the treatment of refractory renal graft rejection.
Acute rejection episodes still occur after kidney transplantation in spite of modern immunosuppressive protocols including combined tacrolimus, mycophenolate mofetil, and prednisolone. The authors present seven cases of biopsy-proven acute rejection after kidney transplantation refractory to conventional rejection therapy with repeated pulses of high-dose steroids followed by polyclonal or monoclonal antibodies that responded well to photopheresis treatment. Photopheresis is an atoxic immunomodulatory apheresis-based treatment with no generalized immunosuppressive action; rather, it is directed at suppressing donor-specific T-cell clones. At the last follow-up, 9 to 43 months after transplantation, all patients had functioning grafts, with serum creatinine levels ranging from 105 to 312 microM. The authors conclude that photopheresis treatment contributed to the favorable outcome. Therefore, the authors are presently designing a prospective, randomized trial to evaluate the effect of photopheresis as an adjuvant prophylactic treatment after renal transplantation.
Kumlien
Gunilla
G
Department of Transfusion Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden. gunilla.kumlien@karolinska.se
Genberg
Helena
H
Shanwell
Agneta
A
Tydén
Gunnar
G
D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D017893:Photopheresis